TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB has released its interim report for January to September 2025, highlighting significant financial and operational developments. Despite reporting no net revenue and a negative result for the period, the company successfully completed a rights issue, raising approximately SEK 84 million. Key milestones include a successful pre-IND meeting with the FDA and progress in their clinical phase Ib/II study of arfolitixorin, which has been well tolerated at the second dose level. These developments underscore Isofol’s commitment to advancing its drug candidate for colorectal cancer treatment.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company is developing a drug candidate, arfolitixorin, aimed at enhancing the effectiveness of first-line standard treatments for various solid tumors, with a current focus on colorectal cancer. Isofol is listed on Nasdaq Stockholm.
Average Trading Volume: 607,355
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK195.5M
For detailed information about ISOFOL stock, go to TipRanks’ Stock Analysis page.